Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
May 21 2024 - 5:30AM
Business Wire
- Chronic gout linked to serious conditions including heart and
kidney disease
- Safe and effective treatments needed more than ever as gout
numbers expected to increase.
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co.,
Ltd.), a clinical stage biotechnology company developing new
treatments for metabolic and inflammatory diseases, such as gout,
is calling for increased understanding of the dangers of chronic
gout to help mark Gout Awareness Day, May 22, 2024. The company
released a video, https://atombp.us/video-gout-awareness-day-2024/
showing hyperuricemia, the cause of gout, can lead to more serious
conditions and the company’s efforts to develop a new
treatment.
“More than 55 million people suffer from gout worldwide, and its
prevalence is increasing yearly,” said William Dongfang Shi, Ph.D.,
Founder and CEO of Atom Bioscience. “Over 9.3 million people in the
U.S. suffer from the disease, and those numbers are expected to
rise. The need for new safe and effective treatments has never been
greater. Patients also should understand that chronic gout has been
linked to many diseases including heart attacks and kidney
disease.”
Atom is enrolling patients in the US for a Phase 2b/3 clinical
trial of ABP-671, a novel orally administered URAT1 inhibitor, for
the treatment of chronic gout (See clinicaltrials.gov
NCT05818085).
Gout is one of the most common types of inflammatory arthritis.
It is caused by a long-term condition known as hyperuricemia,
defined as excessive uric acid levels in the blood (> 7 mg/dL).
The build-up of uric acid is caused by genetic mutations in uric
acid transport mechanisms in the kidney and bowel.
When the transporters don’t function, uric acid is not properly
excreted from the body. Excessive uric acid can lead to the
formation of crystals in joints and soft tissues, causing
debilitating inflammation and the development of urate kidney
stones.
About Atom Bioscience
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co.
Ltd.) is a fast-growing innovative drug company, focused on
development of best in class small molecule therapeutics for
treatment of inflammatory and metabolic diseases. The company’s
lead product, ABP-671, is in clinical development for treatment of
chronic gout. For more information please visit:
https://atombp.us/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521844793/en/
Media Contact: Daniel Eramian Opus Biotech Communications
http://opusbiotech.com/ 425-306-8716